Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10.
about
High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocolEuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytesEuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocolsEuroFlow: Resetting leukemia and lymphoma immunophenotyping. Basis for companion diagnostics and personalized medicineCurrent Strategies for the Detection of Minimal Residual Disease in Childhood Acute Lymphoblastic LeukemiaDiagnosis and subclassification of acute lymphoblastic leukemiaAssessment of bone marrow involvement in patients with lymphoma: report on a consensus meeting of the Korean Society of Hematology Lymphoma Working PartyMinimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical ApplicationsComparable flow cytometry data can be obtained with two types of instruments, Canto II, and Navios. A GEIL study.Acute promyelocytic leukemia: an experience on 95 greek patients treated in the all-trans-retinoic Acid era18α-Glycyrrhetinic Acid Induces Apoptosis of HL-60 Human Leukemia Cells through Caspases- and Mitochondria-Dependent Signaling Pathways.Decreased Vision as Initial Presenting Symptom of Acute Lymphoblastic Leukemia: A Case ReportDiagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.Sensitivity of minimal residual disease in acute myeloid leukaemia in first remission--methodologies in relation to their clinical situation.Immunophenotyping of selected hematologic disorders--focus on lymphoproliferative disorders with more than one malignant cell population.Therapeutic targeting of CD19 in hematological malignancies: past, present, future and beyond.Flow cytometry in hematological disorders.Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS - part IV - postanalytic considerations.ICSH: on board for new projects.Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: past, present and future.Diagnosing and following adult patients with acute myeloid leukaemia in the genomic age.[Leukemia research in Germany: the Competence Network Acute and Chronic Leukemias].Flow cytometry immunophenotyping in integrated diagnostics of patients with newly diagnosed cytopenia: one tube 10-color 14-antibody screening panel and 3-tube extensive panel for detection of MDS-related features.Leukemia diagnosis: today and tomorrow.Immunophenotypic aberrancies in acute lymphoblastic leukemia from 282 Iraqi patients.Advances and issues in flow cytometric detection of immunophenotypic changes and genomic rearrangements in acute pediatric leukemia.Visualization of cell composition and maturation in the bone marrow using 10-color flow cytometry and radar plots.Ten-color 15-antibody flow cytometry panel for immunophenotyping of lymphocyte population.Dendritic cells in bone marrow at diagnosis and after chemotherapy in adult patients with acute myeloid leukaemia.Value of multifaced approach diagnosis and classification of acute leukemias.Adult T-cell leukemia/lymphoma with an unusual CD1a positive phenotype.Morphology and immunophenotyping issues in the integrated diagnosis of hematologic disorders of elderly patients.T/B ratio does not reflect levels of ZAP70 expression in clonal CLL B-cells due to ZAP70 overexpression in patient T-cells.Very low levels of surface CD45 reflect CLL cell fragility, are inversely correlated with trisomy 12 and are associated with increased treatment-free survival.Expression of the hMICL in acute myeloid leukemia-a highly reliable disease marker at diagnosis and during follow-up.hMICL and CD123 in combination with a CD45/CD34/CD117 backbone - a universal marker combination for the detection of minimal residual disease in acute myeloid leukaemia.SNAP-Tag Technology: A Promising Tool for Ex Vivo Immunophenotyping.Rituximab in the management of acute lymphoblastic leukemia.AIEOP-BFM consensus guidelines 2016 for flow cytometric immunophenotyping of Pediatric acute lymphoblastic leukemia.Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemia.
P2860
Q23749304-1D2D5A40-1289-4443-9DA2-157B4FE2E247Q24604581-CB93A138-F870-48A7-BD09-824FD4198140Q24604720-36D6629D-8EE7-4E54-A077-C93A78631D87Q24605023-2F983990-20F8-47A2-A9D3-9B558DEFE7EEQ26751269-6E0A2D97-0F82-4011-AFAF-C24F2BBA3D53Q26824387-BA1CF3AC-F819-48E2-B8B1-4352B2A19336Q28073223-8D9EFEB6-CFC5-4331-BAED-B9262856224BQ28073464-96DAC920-20FF-41FE-BE42-1D3C1693DAF0Q30682927-BBAFBE5B-E381-490C-BBCB-2496268B2751Q35640734-D16040F5-9356-481C-88C1-96DD4467074FQ36067419-C4542436-3D6B-4F62-949C-3BD5CEE3A2D3Q37298657-C82EE88B-6677-4B38-8623-61CC28961F0CQ37624593-BFB60467-3ECE-4FEC-8F21-D840E7A1449DQ38022075-6467178E-DADF-42D8-A69D-3D8D7CA074A1Q38099421-16853C48-DD1A-4B23-BE2C-093A67A87658Q38124065-6CD8FB63-33FA-4568-A940-4AE1213CC773Q38128814-D3BEE590-BD62-405E-A792-1A7A026D4239Q38136152-C989A9A6-8FF4-4CCB-94FB-85B82EC605A4Q38205950-8DF8E275-60D5-424D-81EA-E22E681946F7Q38212956-CD33D06A-CBCE-4FA1-B410-77D178354F45Q38240563-55C882E7-9864-4143-9E5D-EB8D89B14C2DQ38382105-E2F87A90-0E33-4B1B-B8F1-D6523A232F99Q38482013-0502BA2F-9585-4F7D-9DEC-B0FD6301251AQ38537725-05E13628-3784-49A9-85EE-7FEE52B77E65Q38655375-AD2F86F8-319D-40B3-A454-38DF51FAA7A7Q38719359-95E22C6D-EE6A-47AD-B803-0E85A27E4B1FQ38930842-48BF29D3-788E-4BBA-BC84-F5B38E0926F2Q39266366-20E3DAD0-FAC2-4202-8A9D-7E59BA6980A7Q41688469-2BD8B9E5-858B-41A8-9D08-B0BC3C006634Q42000062-BB3FA965-ECE6-432C-9440-C087F1152BEFQ42263346-3C0F3074-28F4-4E7A-AB14-C67BD093DEAFQ42609619-546D8359-5021-43AF-A679-28B92796B2BDQ43498163-3B7D030E-EC4B-4632-827B-F548B25019BBQ44052238-1B506A90-E1E2-41F3-B91C-7007BDF8BF51Q44059514-19FD4177-1990-4D5E-A7D6-58D7E92E5177Q44222759-A07919A2-470F-4933-B307-6E11876F1A85Q46475052-7F781706-5C2F-4086-B26B-D42B7AC5AE7EQ47196522-BB8DB751-4DD2-4782-A338-EE609F427977Q47976103-1C1B9323-9DEA-4391-9A77-7534EC67EFF4Q48154986-CF9A4B08-2D43-4FBC-B060-7F388BF0AD3B
P2860
Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Immunophenotyping of acute leu ...... n LeukemiaNet Work Package 10.
@en
Immunophenotyping of acute leu ...... n LeukemiaNet Work Package 10.
@nl
type
label
Immunophenotyping of acute leu ...... n LeukemiaNet Work Package 10.
@en
Immunophenotyping of acute leu ...... n LeukemiaNet Work Package 10.
@nl
prefLabel
Immunophenotyping of acute leu ...... n LeukemiaNet Work Package 10.
@en
Immunophenotyping of acute leu ...... n LeukemiaNet Work Package 10.
@nl
P2093
P2860
P356
P1433
P1476
Immunophenotyping of acute leu ...... n LeukemiaNet Work Package 10.
@en
P2093
A M Vladareanu
G Tschurtschenthaler
P2860
P2888
P304
P356
10.1038/LEU.2010.312
P577
2011-01-21T00:00:00Z